Details of the Drug Pharmacogenomic Perturbation Atlas
General Information of Drug (ID: DMWP1BH)
| Drug Name | ||||||
|---|---|---|---|---|---|---|
| Synonyms |
EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-
| |||||
| Cross-matching ID | ||||||
Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
|
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||
Pharmacogenomic Perturbation Across Diseases and Tissues
|
Bone
Osteosarcoma
Bone marrow
Chronic myeloid leukemia
Multiple myeloma
Lung
Lung adenocarcinoma
Lymph node
Burkitt lymphoma
Diffuse large B-cell lymphoma
Mantle cell lymphoma
Peripheral blood
Acute B-lymphoblastic leukemia
Acute monocytic leukemia
Prostate
Prostate carcinoma
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
